173 related articles for article (PubMed ID: 20700755)
1. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
2. Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line.
Leng L; Zhang Y
J Clin Neurosci; 2011 Dec; 18(12):1694-8. PubMed ID: 22015101
[TBL] [Abstract][Full Text] [Related]
3. Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.
Lv H; Li C; Gui S; Zhang Y
J Endocrinol Invest; 2012 Feb; 35(2):174-80. PubMed ID: 21422801
[TBL] [Abstract][Full Text] [Related]
4. Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models.
Cao L; Gao H; Gui S; Bai G; Lu R; Wang F; Zhang Y
J Neurooncol; 2014 Feb; 116(3):523-31. PubMed ID: 24407733
[TBL] [Abstract][Full Text] [Related]
5. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
6. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Cao L; Gao H; Li P; Gui S; Zhang Y
Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
8. Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines.
Selek A; Halbutoğulları ZSU; Aydemir Çİ; Cetinarslan B; Canturk Z; Tarkun I; Erman G; Subaşı C; Erdal K
Mol Neurobiol; 2023 May; 60(5):2442-2454. PubMed ID: 36662360
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
Wang C; Hu ZQ; Chu M; Wang Z; Zhang WG; Wang LZ; Li CG; Wang JS
Clin Neurol Neurosurg; 2012 Apr; 114(3):241-8. PubMed ID: 22104698
[TBL] [Abstract][Full Text] [Related]
10. Up- and Down-regulated Leukemia-related Protein 16 Affects ERα Expression and Prolactin Secretion by GH3 Cells.
Su X; Wu ZQ; Yang XJ; Wang AP; Zhao K; Wu TG; Sun Y; Sun J; Chang ZY; Guo XY; Guo QH; Mu YM
Biomed Environ Sci; 2017 Dec; 30(12):938-942. PubMed ID: 29335066
[TBL] [Abstract][Full Text] [Related]
11. 17β-estradiol binding to ERα promotes the progression of prolactinoma through estrogen-response element-induced CaBP-9k up-regulation.
Liu J; Han H; Lu W; Fan G
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894842
[TBL] [Abstract][Full Text] [Related]
12. Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism.
Li C; Sun Z; Gui S; Liu F; Zhang Y
Neuro Endocrinol Lett; 2009; 30(2):268-74. PubMed ID: 19675520
[TBL] [Abstract][Full Text] [Related]
13. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk.
Paez-Pereda M; Giacomini D; Refojo D; Nagashima AC; Hopfner U; Grubler Y; Chervin A; Goldberg V; Goya R; Hentges ST; Low MJ; Holsboer F; Stalla GK; Arzt E
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1034-9. PubMed ID: 12552124
[TBL] [Abstract][Full Text] [Related]
14. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
15. Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors.
Shupnik MA; Pitt LK; Soh AY; Anderson A; Lopes MB; Laws ER
J Clin Endocrinol Metab; 1998 Nov; 83(11):3965-72. PubMed ID: 9814476
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.
Kansra S; Yamagata S; Sneade L; Foster L; Ben-Jonathan N
Mol Cell Endocrinol; 2005 Jul; 239(1-2):27-36. PubMed ID: 15950373
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
19. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
20. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis.
Heaney AP; Horwitz GA; Wang Z; Singson R; Melmed S
Nat Med; 1999 Nov; 5(11):1317-21. PubMed ID: 10546001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
